Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Leases (2020 - 2025)

Anaptysbio's Current Leases history spans 6 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Current Leases rose 8.05% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 8.05%, while the annual FY2025 figure was $2.1 million, 8.05% up from the prior year.
  • Current Leases reached $2.1 million in Q4 2025 per ANAB's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.1 million in Q4 2025 to a low of $555000.0 in Q2 2021.
  • Average Current Leases over 5 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Current Leases: skyrocketed 340.06% in 2021, then increased 8.05% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.5 million in 2021, then grew by 8.77% to $1.6 million in 2022, then increased by 8.55% to $1.8 million in 2023, then rose by 8.33% to $1.9 million in 2024, then increased by 8.05% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Current Leases are $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).